Table 5.
Plasma concentrations of soluble receptor for advanced glycation end products (sRAGE) and ratios of sRAGE versus advanced glycation end products (AGE), during gestation and prior to the onset of preeclampsia.
| DM+PE+ (n = 23) | p value∗ | DM+PE- (n = 24) | p value# | DM- (n = 19) | ||
|---|---|---|---|---|---|---|
| sRAGE† | V1 | 907 ± 324 | 0.08 | 1102 ± 405 | 0.76 | 1146 ± 473 |
| V2 | 942 ± 282 | 0.018 | 1219 ± 438 | 0.93 | 1231 ± 464 | |
| V3 | 929 ± 465 | 0.64 | 984 ± 325 | 0.58 | 923 ± 399 | |
|
| ||||||
| sRAGE/CML‡ | V1 | 18.2 ± 7.3 | 0.13 | 25 ± 18 | 0.42 | 21 ± 12 |
| V2 | 16.8 ± 7.0 | 0.037 | 23 ± 11 | 0.23 | 28 ± 13 | |
| V3 | 16 ± 12 | 0.84 | 26 ± 8.4 | 0.84 | 16.1 ± 8.6 | |
|
| ||||||
| sRAGE/CEL‡ | V1 | 30 ± 11 | 0.37 | 34 ± 22 | 0.92 | 35 ± 13 |
| V2 | 27 ± 12 | 0.019 | 38 ± 17 | 0.68 | 40 ± 17 | |
| V3 | 24 ± 15 | 0.93 | 24 ± 11 | 0.33 | 28 ± 14 | |
|
| ||||||
| sRAGE/MGH1‡ | V1 | 19 ± 10 | 0.72 | 21 ± 18 | 0.73 | 23 ± 12 |
| V2 | 18 ± 14 | 0.87 | 19 ± 12 | 0.96 | 19 ± 11 | |
| V3 | 14 ± 12 | 0.47 | 11.5 ± 9.8 | 0.38 | 14 ± 11 | |
|
| ||||||
| sRAGE/3DGH‡ | V1 | 5.9 ± 2.7 | 0.67 | 6.2 ± 2.8 | 0.07 | 8.2 ± 3.8 |
| V2 | 5.9 ± 2.0 | 0.15 | 7.0 ± 2.9 | 0.07 | 9.1 ± 4.1 | |
| V3 | 4.8 ± 3.2 | 0.65 | 5.2 ± 2.9 | 0.68 | 5.6 ± 3.6 | |
|
| ||||||
| sRAGE/GH1‡ | V1 | 249 ± 100 | 0.97 | 250 ± 157 | 0.40 | 288 ± 115 |
| V2 | 255 ± 115 | 0.47 | 283 ± 133 | 0.99 | 283 ± 140 | |
| V3 | 175 ± 108 | 0.80 | 183 ± 90 | 0.76 | 175 ± 87 | |
Data are presented as means ± SD. Units: †pg/mL; ‡g/moles. Independent sample t tests were used as appropriate. Boldface indicates p values < 0.05 (statistically significant). ∗p value, DM+PE- vs. DM+PE+. #p value, DM+PE- vs. DM-.